Antitumor Activity of Axitinib in Lung Carcinoids: A Preclinical Study

被引:2
|
作者
Dicitore, Alessandra [1 ]
Gaudenzi, Germano [2 ]
Carra, Silvia [3 ]
Cantone, Maria Celeste [2 ]
Oldani, Monica [2 ]
Saronni, Davide [1 ]
Borghi, Maria Orietta [4 ,5 ]
Grotteschi, Jacopo [1 ]
Persani, Luca [1 ,3 ]
Vitale, Giovanni [1 ,2 ]
机构
[1] Univ Milan, Dept Med Biotechnol & Translat Med, I-20122 Milan, Italy
[2] Ist Auxol Italiano, IRCCS, Lab Geriatr & Oncol Neuroendocrinol Res, Milan I-20145, Italy
[3] Ist Auxol Italiano, IRCCS, Lab Endocrine & Metab Res, I-20145 Milan, Italy
[4] Univ Milan, Dept Clin Sci & Community Hlth, I-20122 Milan, Italy
[5] Ist Auxol Italiano, IRCCS, Expt Lab Immuno Rheumatol, I-20145 Milan, Italy
关键词
lung carcinoid; tyrosine kinase inhibitors; axitinib; cell cycle; apoptosis; zebrafish; tumor xenograft; ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; PHASE-II; NEUROENDOCRINE TUMORS; MICROVASCULAR DENSITY; ENDOCRINE TUMORS; OPEN-LABEL; ANGIOGENESIS; EXPRESSION; SUNITINIB;
D O I
10.3390/cancers15225375
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Lung carcinoids (LCs) are categorized as low- and intermediate-grade neuroendocrine tumors. Surgery is effective for localized LCs with a favorable prognosis. However, there is a pressing need for new treatments for unresectable and metastatic LCs. This study explored the potential antitumor effects of axitinib using both in vitro (immortalized cell lines) and in vivo (zebrafish) LC models. Axitinib demonstrated significant antitumor activity by reducing cell viability, inducing cell cycle arrest, and promoting cell death. Moreover, axitinib had a notable impact on crucial processes in tumor progression, including tumor-induced angiogenesis and invasiveness.Abstract Lung carcinoids (LCs) comprise well-differentiated neuroendocrine tumors classified as typical (TCs) and atypical (ACs) carcinoids. Unfortunately, curative therapies remain elusive for metastatic LCs, which account for 25-30% of cases. This study evaluated the antitumor activity of axitinib (AXI), a second-generation tyrosine kinase inhibitor selectively targeting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3) in human lung TC (NCI-H727, UMC-11, NCI-H835) and AC (NCI-H720) cell lines. In vitro and in vivo (zebrafish) assays were performed following AXI treatment to gather several read-outs about cell viability, cell cycle, the secretion of proangiogenic factors, apoptosis, tumor-induced angiogenesis and migration. AXI demonstrated relevant antitumor activity in human LC cells, with pronounced effects observed in UMC-11 and NCI-H720, characterized by cell cycle perturbation and apoptosis induction. AXI significantly hindered tumor induced-angiogenesis in Tg(fli1a:EGFP)y1 zebrafish embryos implanted with all LC cell lines and also reduced the invasiveness of NCI-H720 cells, as well as the secretion of several proangiogenic factors. In conclusion, our study provides initial evidence supporting the potential anti-tumor activity of AXI in LC, offering a promising basis for future investigations in mammalian animal models and, eventually, progressing to clinical trials.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Exploring the multifaceted antitumor activity of axitinib in lung carcinoids
    Oldani, Monica
    Cantone, Maria Celeste
    Gaudenzi, Germano
    Carra, Silvia
    Dicitore, Alessandra
    Saronni, Davide
    Borghi, Maria Orietta
    Lombardi, Angela
    Caraglia, Michele
    Persani, Luca
    Vitale, Giovanni
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [2] Antitumor Activity of Theophylline in Combination with Paclitaxel: A Preclinical Study on Melanoma Experimental Lung Metastasis
    Lentini, Alessandro
    Tabolacci, Claudio
    Mattioli, Palma
    Provenzano, Bruno
    Beninati, Simone
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2010, 25 (04) : 497 - 503
  • [3] Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib
    Ma, Jie
    Waxman, David J.
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (01) : 79 - 89
  • [4] Preclinical antitumor activity of bizelesin in mice
    Carter, CA
    Wand, WR
    Li, LH
    DeKoning, TF
    McGovren, JP
    Plowman, J
    CLINICAL CANCER RESEARCH, 1996, 2 (07) : 1143 - 1149
  • [5] PRECLINICAL PHARMACOKINETICS AND ANTITUMOR-ACTIVITY OF IMEXON
    DORR, RT
    LIDDIL, JD
    KLEIN, MK
    HERSH, EM
    INVESTIGATIONAL NEW DRUGS, 1995, 13 (02) : 113 - 116
  • [6] Preclinical evaluation of aromatase inhibitors antitumor activity
    Auvray, P
    Bichat, F
    Genne, P
    BULLETIN DU CANCER, 2000, : 7 - 22
  • [7] Preclinical antitumor activity of two novel taxanes
    Rose, WC
    Fairchild, C
    Lee, FYF
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 47 (02) : 97 - 105
  • [8] Preclinical antitumor activity of CI-994
    LoRusso, PM
    Demchik, L
    Foster, B
    Knight, J
    Bissery, MC
    Polin, LM
    Leopold, WR
    Corbett, TH
    INVESTIGATIONAL NEW DRUGS, 1996, 14 (04) : 349 - 356
  • [9] Preclinical antitumor activity of two novel taxanes
    William C. Rose
    Craig Fairchild
    Francis Y.F. Lee
    Cancer Chemotherapy and Pharmacology, 2001, 47 : 97 - 105
  • [10] Antitumor activity of interleukin 12 in preclinical models
    Brunda, MJ
    Luistro, L
    Rumennik, L
    Wright, RB
    Dvorozniak, M
    Aglione, A
    Wigginton, JM
    Wiltrout, RH
    Hendrzak, JA
    Palleroni, AV
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 38 : S16 - S21